Journal
NEUROBIOLOGY OF DISEASE
Volume 134, Issue -, Pages -Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2019.104707
Keywords
Tau-targeted immunotherapy; Tau; Amyloid Beta immunotherapy; Alzheimer's disease; Biomarkers extracellular tau; Alzheimer's disease clinical trials
Categories
Funding
- National Institutes of Health [AG054025, RFA1AG055771]
Ask authors/readers for more resources
The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the disease process. However, accumulating evidence from experimental and clinical studies that investigate the early disease process point towards the required role of tau in AD etiology. Importantly, a large number of studies investigate and characterize the plethora of pathological forms of tau protein involved in disease onset and propagation. Immunotherapy is one of the most clinical approaches anticipated to make a difference in the field of AD therapeutics. Tau targeted immunotherapy is the new direction after the failure of amyloid beta (A beta)-targeted immunotherapy and the growing number of studies that highlight the A beta-independent disease process. It is now well established that immunotherapy alone will most likely be insufficient as a monotherapy. Therefore, this review discusses updates on tau-targeted immunotherapy studies, AD-relevant tau species, updates on promising biomarkers and a prospect on combination therapies to surround the disease propagation in an efficient and timely manner.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available